Co-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy
Co-Diagnostics (Nasdaq: CODX) announced that its Logix Smart™ COVID-19 Test Kit was utilized by Italian researchers to detect SARS-CoV-2, including mutated strains, through community surveillance testing of discarded saliva samples. The peer-reviewed results were published in Science of the Total Environment. The study involved testing items like plastic cups and bottles across 20 sites in Northern Italy during the COVID-19 peak in early 2021. CEO Dwight Egan emphasized the importance of this study, highlighting the test's effectiveness in identifying viral presence in environmental samples.
- Successful demonstration of Logix Smart COVID-19 Test in a peer-reviewed study.
- High concordance with sequencing results, confirming the test's reliability.
- Potential for expanded use of the test in community surveillance.
- None.
SALT LAKE CITY, Sept. 8, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by Italian researchers to confirm the presence of SARS-CoV-2, including mutated strains of the virus, in a community surveillance method of testing single-use waste, with the peer-reviewed results published in the journal Science of the Total Environment.
The innovative approach for surveilling communities involved testing the saliva left on single-use glasses and bottles for the presence of SARS-CoV-2 in 20 different sites in Northern Italy during the second peak of COVID-19 in January and February 2021. The objects tested, including plastic coffee cups, plastic glasses, beverage cans, and plastic bottles discarded in snack bars, cafes, schools, and businesses, were swabbed, pooled, and then analyzed at the Istituto Superiore di Sanità using commercially available PCR reagents. Researchers then used Co-Diagnostics' Logix Smart COVID-19 Test to corroborate the results with complete concordance. The positive samples were later sequenced, and some were found to contain the presence of mutated variants of the virus.
Dwight Egan, Chief Executive Officer of Co-Diagnostics, remarked, "We are pleased to add this study to the growing list of scientific literature that supports the value and utility of our testing technology, and specifically our original COVID-19 test that we developed in the earliest days of the pandemic. Demonstrating that the virus can survive in saliva samples on surfaces long enough to allow for surveillance of the community may allow for another tool in the fight against the pandemic, and we believe that the Logix Smart test, built on our patented CoPrimer™ platform, was chosen as the assay to confirm the results due to its reputation as a high-quality SARS-CoV-2 PCR test."
The Science of the Total Environment paper can be found here.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company's liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company's products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company's balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to rely on any forward-looking statements. Any forward-looking statement made by the Company in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-sars-cov-2-test-used-in-new-community-surveillance-method-in-italy-301371392.html
SOURCE Co-Diagnostics
FAQ
What did Co-Diagnostics announce on September 8, 2021?
What is the significance of the Logix Smart™ Test according to the press release?
Where were the results of the study published?
How was the Logix Smart™ Test utilized in the study?
Who commented on the study's findings in the press release?
